The Q32 Bio Inc. (QTTB) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, including current reports on Form 8-K that highlight material events. Q32 Bio’s filings reflect its status as a Nasdaq-listed clinical stage biotechnology company focused on alopecia areata and other autoimmune and inflammatory diseases.
Recent Form 8-K filings referenced by Q32 Bio include reports furnished under Item 2.02 for quarterly financial results and corporate updates, and under Item 8.01 for other events such as clinical trial milestones. For example, the company has filed 8-Ks in connection with press releases announcing financial results for specific quarters, as well as an 8-K describing the completion of enrollment in Part B of the SIGNAL-AA Phase 2a clinical trial of bempikibart for alopecia areata. Another 8-K details leadership changes under Item 5.02, including the resignation of a Chief Medical Officer and the appointment of an interim Chief Medical Officer.
Q32 Bio’s 8-K filings also confirm that its common stock, with a par value of $0.0001 per share, is registered pursuant to Section 12(b) of the Exchange Act and trades on Nasdaq under the symbol QTTB. The filings typically attach press releases as exhibits, which are incorporated by reference where specified, and clarify whether the information is being furnished rather than filed for purposes of Section 18 of the Exchange Act.
On Stock Titan, these SEC documents are updated as they become available from EDGAR and are paired with AI-powered summaries that explain the key points in accessible language. Users can quickly see which filings relate to financial results, clinical trial updates, leadership changes, or other corporate events, and can review the underlying forms and exhibits for more detail.
Q32 Bio Inc. reported a sharp turnaround to profitability for the quarter and year ended December 31, 2025, driven by collaboration revenue and an asset sale. Quarterly collaboration arrangement revenue was $53.7 million, supporting net income of $57.7 million, or $4.60 basic earnings per share, versus a net loss in the prior-year quarter.
For full-year 2025, Q32 Bio generated net income of $29.8 million, or $2.42 basic earnings per share, compared with a $47.7 million net loss in 2024. The swing was primarily due to non-cash collaboration revenue recognized under the amended Amgen agreement and the gain on sale of ADX‑097 to Akebia Therapeutics.
Cash and cash equivalents were $48.3 million as of December 31, 2025. Combined with gross proceeds from a $10.5 million registered direct offering completed in February 2026 and guaranteed near-term milestone payments from the ADX‑097 sale, the company expects funding to last into the fourth quarter of 2027.
Operationally, Q32 Bio completed enrollment in Part B of its SIGNAL‑AA Phase 2a trial of bempikibart in severe alopecia areata, expanding to 33 patients, with a 36‑week topline data readout anticipated in mid‑2026. An open-label extension from Part A remains ongoing to assess longer-term outcomes.
Q32 Bio Inc. executive Lee Kalowski, the CFO and President, reported an automatic sale of 3,995 shares of common stock on February 25, 2026 to cover tax withholding tied to vesting of restricted stock units. The weighted average sale price was $4.5144 per share, with individual trades ranging from $4.35 to $4.69. After these transactions, Kalowski directly owned 35,943 shares of Q32 Bio common stock.
Q32 Bio Inc. CEO and director Jodie Pope Morrison reported an open-market sale of 9,896 shares of common stock on February 25, 2026 at a weighted average price of $4.5144 per share. According to the disclosure, these shares were required to be sold to cover tax withholding obligations related to the vesting of restricted stock units, and the sales were automatic and not at her discretion. The trades occurred in multiple transactions at prices ranging from $4.35 to $4.69 per share. After these sales, she directly owned 89,104 Q32 Bio shares.
Q32 Bio Inc. Chief Scientific Officer Shelia M. Violette reported an automatic sale of 2,815 shares of common stock on February 25, 2026 to cover tax withholding from vesting restricted stock units. The weighted average sale price was $4.5144 per share, across trades between $4.35 and $4.69.
After this sale, she held 55,569 shares directly. An additional 36,277 shares were reported as held indirectly through Violette Holdings LLC, for which she disclaims beneficial ownership except for any pecuniary interest.
Q32 Bio Inc. ownership filing: Opaleye Management Inc., together with Opaleye, L.P. and James Silverman, reports beneficial ownership of 1,256,228 shares of Common Stock, representing 8.65% of the class.
The filing states the share count is based on 14,524,726 Common Shares outstanding as of 02/17/2026, cited from Q32 Bio Inc.'s 424B5 Prospectus.
Q32 Bio Inc. ownership disclosure: Point72 entities and Steven A. Cohen report shared beneficial ownership of 2,057,308 shares, representing 9.9% of the common stock as of the close of business on February 18, 2026.
The cover-page total includes 1,025,654 shares issuable upon exercise of warrants; certain warrants are subject to a verbatim "9.99% Blocker" that limits exercisability and reduces the actual exercisable share count. Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen each report shared voting and dispositive power over the reported shares.
Q32 Bio Inc. entered into a definitive agreement for a registered direct offering raising approximately $10.5 million in gross proceeds. The company will sell 1,666,679 shares of common stock at $3.90 per share and issue pre-funded warrants to purchase up to 1,025,654 shares at $3.8999 per warrant, with a nominal exercise price of $0.0001 per share. The pre-funded warrants are immediately exercisable but subject to a 9.99% beneficial ownership cap. Q32 Bio plans to use the net proceeds, along with existing cash and securities, for working capital, including research, clinical development and commercialization efforts, and to advance its alopecia areata candidate bempikibart into future clinical trials.
Q32 Bio is offering 1,666,679 shares of common stock and pre-funded warrants to purchase up to 1,025,654 shares, raising approximately $10.5 million before expenses at $3.90 per share. The pre-funded warrants are priced at $3.8999 and carry a nominal exercise price of $0.0001 per share.
Net proceeds of about $10.3 million will fund working capital, research and clinical development, particularly advancing lead antibody bempikibart for alopecia areata and future trials. The company highlights that investors will experience immediate and substantial dilution, and future equity financings could further dilute existing holders.
Pre-funded warrants are immediately exercisable, do not trade on any exchange and have beneficial ownership limits, generally capped at up to 19.99% (with lower 4.99% or 9.99% options), which can restrict exercises for larger holders. Q32 Bio remains a smaller reporting company with reduced disclosure requirements and emphasizes the high risks typical of early-stage biotechnology development.
Pfizer Inc. has filed an amended Schedule 13G reporting a passive minority stake in Q32 Bio Inc. Pfizer reports beneficial ownership of 277,777 shares of Q32 Bio common stock, representing 2.3% of the outstanding shares.
The ownership percentage is based on 12,304,352 Q32 Bio common shares outstanding as of November 1, 2025, as disclosed by the company. Pfizer notes that its holdings trace back to shares it previously reported in Homology Medicines, Inc., which merged into Q32 Bio with Q32 Bio as the surviving entity.
Pfizer certifies that the securities were not acquired and are not held for the purpose of changing or influencing control of Q32 Bio, confirming this is a passive investment position below the 5% threshold.
Q32 Bio director Kathleen LaPorte reported a new stock option grant. On 01/15/2026, she received a stock option to buy 23,272 shares of Q32 Bio Inc. common stock with a $3.60 exercise price, under the 2024 Stock Option and Incentive Plan and the non-employee director compensation policy.
The option vests in four equal quarterly installments on the last day of each calendar quarter, as long as she continues serving as a director. LaPorte elected to receive stock options instead of cash retainer fees, and the company notes this award was initially omitted from prior reports due to administrative oversight.